Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin

Human and Experimental Toxicology

Volumn 34, Issue 8, 2015, Pages 828-837

  Farag, M M ^a   Mohamed, M B ^a   Youssef, E A ^b  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

acetaminophen; Atorvastatin; hepatoprotection; hepatotoxicity; liver function; oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; GLUTATHIONE; MALONALDEHYDE; PARACETAMOL; SUPEROXIDE DISMUTASE; ANTIOXIDANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZING AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; LIPID LIVER LEVEL; LIPID PEROXIDATION; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER HISTOLOGY; LIVER NECROSIS; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANIMAL; DRUG EFFECTS; LIVER; LIVER FUNCTION TEST; METABOLISM; PATHOPHYSIOLOGY;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; RATTUS;

ACETAMINOPHEN; ANIMALS; ANTIOXIDANTS; ATORVASTATIN CALCIUM; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER FUNCTION TESTS; OXIDANTS; RATS;

EID: 84938094631     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327114559991     Document Type: Article

References (44)

1. Malhotra H, Goa K,. Atorvastatin. An updated review of its pharmacological properties and use in dyslipidemia. Drugs 2001; 61: 1835-1881.
2. Athyros VG, Tzimalos K, Gossios TD,. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary heart disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 2010; 376: 1916-1922.
3. Neuvonen PJ, Niemi M, Backman JT,. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 56-81.
4. Zhang H, Plutzky J, Skentzos S,. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158: 526-534.
5. Russo MW, Scobey M, Bonkovsky HL,. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29: 412-422.
6. Macedo AF, Taylor FC, Cases JP,. Unintended effects of statins from observational studies in the general population: systemic review and meta-analysis. BMC Med 2014: 12: 51.
7. Clarke AT, Mills PR,. Atorvastatin associated liver disease. Dig Liver Dis 2006; 8: 772-777.
8. Rahier JF, Rahier J, Ladlers I,. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol Belg 2008; 71: 318-320.
9. Navarro VJ, Senior JR,. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.
10. Silva M, Matthews ML, Jarvis C,. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007; 29: 253-260.
11. Björnsson E, Jacobsen EI, Kalaitzakis E,. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56: 374-380.
12. Bolego C, Baetta R, Bellosta S,. Safety considerations for statins. Curr Opin Lipidol 2002; 13: 637-644.
13. Foster T, Budoff MJ, Saab S,. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106: 71-77.
14. Jaeschke H, Gores GJ, Cederbaum AI,. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-176.
15. Yuan L, Kaplowitz N,. Glutathione in liver disease and hepatotoxicity. Mol Aspects Med 2009; 30: 29-41.
16. Jaeschke H, Knight TR, Bajt ML,. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett 2003; 144: 279-288.
17. Mc Gill MR, Jaeschke H,. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res 2013; 30: 2174-2187.
18. Black AE, Hayes RN, Roth BD,. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 1999; 27: 916-923.
19. Pierno S, Didonna MP, Cippone V,. Effects of chronic treatment with statins and fenofibrate on skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol 2006; 149: 909-919.
20. Jones P, Alone S, Laurora I,. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES). Am J Cardiol 1998; 81: 582-587.
21. Stein EA,. The power of statins: aggressive lipid lowering. Clin Cardiol 2003; 26: 25-31.
22. Youssef S, Stuve O, Patarroyo JC,. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
23. Mitchell JR, Jollow DJ, Potter WZ,. Acetaminophen-induced hepatic necrosis. I: role of drug metabolism. J Pharmacol Exp Ther 1973; 187: 185-194.
24. Kondo K, Yamada N, Suzuki Y,. Enhancement of acetaminophen-induced chronic hepatotoxicity in restricted fed rats: a nonclinical approach to acetaminophen-induced chronic hepatotoxicity in susceptible patients. J Toxicol Sci 2012; 37: 911-929.
25. Richardson RJ, Murphy SD,. Effect of glutathione depletion on tissue deposition of methyl mercury in rats. Toxicol Appl Pharmacol 1975; 31: 505-519.
26. Draper HH, Hadley M,. Malondialdehyde determination as index of lipid peroxidation. Meth Enzymol 1990; 618: 421-425.
27. Marklund S, Marklund G,. Involvement of superoxide anion radical in autoxidation of pyrogallol and a convenient assay for SOD. Europ J Biochem 1974; 7: 469-474.
28. Lee WM, Senior JR,. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005; 33: 155-164.
29. Ramachandran R, Kakar S,. Histological patterns in drug-induced liver disease. J Clin Pathol 2009; 62: 481-492.
30. Mc Cord JM,. Human disease, free radicals and the oxidant/antioxidant balance. Clin Biochem 1993; 26: 35-37.
31. Ma Q,. Transcriptional responses to oxidative stress: pathological and toxicological implications. Pharmacol Ther 2010; 125: 376-393.
32. Sánchez-Valle V, Chávez-Tapia NC, Rube M,. Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem 2012; 19: 4850-4860.
33. Landis GN, Tower J,. Superoxide dismutase evolution and life span regulation. Mech Ageing Dev 2005; 126: 365-379.
34. Yoshikawa T, Naito Y,. What is oxidative stress? JMAJ 2002; 45: 271-276.
35. Circu ML, Aw TY,. Reactive oxygen species, cellular redox systems and apoptosis. Free Radic Biol Med 2010; 48: 749-762.
36. Malhotra H, Goa K,. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidemia. Drugs 2001; 61: 1835-1881.
37. Stadtman ER, Berlett BS,. Reactive oxygen-mediated protein oxidation in ageing and disease. Chem Res Toxicol 1997; 10: 485-494.
38. Long J, Liu C, Sun L,. Neuronal mitochondrial toxicity of malondialdehyde: inhibitory effects on respiratory function and enzyme activities in rat brain mitochondria. Neurochem Res 2009; 34: 786-794.
39. Lee WM,. Acute liver failure in the United States. Semin Liver Dis 2003; 23: 217-226.
40. Watkins PB, Kaplowitz N, Slattery JT,. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87-93.
41. Dahlin DC, Miwa GT, Lu AYH,. N-Acetyl- p -benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 1984; 81: 1327-1331.
42. Aviram M, Rosenblat M, Bisgaier CL,. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-280.
43. Sugiyama M, Ohashi M, Teaks H,. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 2005; 20: 133-136.
44. Moreno M, Ramalho LN, Sancho-Bru P,. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009; 296: G147-G156.